RxDoctor Payments Data

Sean Flynn, DO

Internal Medicine · Havertown, PANPI 1386888121

Payments from drug & device makers

$273in general payments, 2019–2025

Across 10 payments — averaging $27.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$125
  • GSK$44
  • Bayer$36
  • Collegium Pharmaceutical, Inc.$21
  • Alkermes, Inc.$19
  • Merck$17
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$273100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$273 in reported general payments places this provider in the 55th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$164,078
Medicare patients
473
Services billed
1,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin115$132,300
OzempicSemaglutide112$117,006
EliquisApixaban78$69,108
TrulicityDulaglutide55$52,061
MounjaroTirzepatide41$45,876
JanuviaSitagliptin Phosphate43$42,740
CreonLipase/Protease/Amylase36$42,632
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$31,270
Breo ElliptaFluticasone/Vilanterol66$28,152
MyrbetriqMirabegron21$14,921
LinzessLinaclotide17$14,916
XareltoRivaroxaban14$12,510
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$10,249
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$9,303
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$8,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$44$72,535140 claims
MerckJanuvia$17$42,74043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Havertown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →